Business
Novartis delivered high single-digit sales growth, achieved 40% core margin and further advanced the pipeline in 2025
Ad hoc announcement pursuant to Art. 53 LRFull yearNet sales grew +8% (cc1, +8% USD) with core operating income1 up +14% (cc, +12% USD) Sales growth driven by continued strong performance from priority brands including Kisqali (+57% cc), Kesimpta (+36% cc), Pluvicto (+42% cc), Scemblix (+85% cc) and Cosentyx (+8% cc)Core operating income margin1 was 40.1%, +210 basis points (cc)Operating income grew +25% (cc, +21% USD); net income up +19% (cc, +17% USD)Core EPS1 grew +17% (cc, +15% USD) to USD 8
About this update from Novartis Ag
[{"type":"image","alt":"Novartis Pharma AG","displaySize":"","headline":null,"caption":"Novartis Pharma AG","className":"","disableSlideshowImg":false,"size":{"original":{"width":287,"height":55,"url":"https://media.zenfs.com/en/globenewswire.com/838a2f0cbe482ce95bb28a161721a308"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/jVHT.jc1r.9_PBg7JQVa4A--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTgwO2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/838a2f0cbe482ce95bb28a161721a308","width":287,"height":55}},"lazy":false},{"type":"text","content":"Ad hoc announcement pursuant to Art. 53 LR","length":42,"tagName":"p"},{"type":"text","content":"Full year","length":9,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Net sales grew +8% (cc1, +8% USD) with core operating income1 up +14% (cc, +12% USD) ","length":84,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Sales growth driven by continued strong performance from priority brands including Kisqali (+57% cc), Kesimpta (+36% cc), Pluvicto (+42% cc), Scemblix (+85% cc) and Cosentyx (+8% cc)","length":182,"tagName":"p"}]},{"val":[{"type":"text","content":"Core operating income margin1 was 40.1%, +210 basis points (cc)","length":63,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":245,"olType":false}]},{"val":[{"type":"text","content":"Operating income grew +25% (cc, +21% USD); net income up +19% (cc, +17% USD)","length":76,"tagName":"p"}]},{"val":[{"type":"text","content":"Core EPS1 grew +17% (cc, +15% USD) to USD 8.98","length":46,"tagName":"p"}]},{"val":[{"type":"text","content":"Free cash flow1 of USD 17.6 billion (+8% USD) driven by higher net cash flows from operating activities","length":103,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":554,"olType":false},{"type":"text","content":"Fourth quarter","length":14,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Net sales -1% (cc, +1% USD), impacted by US generic erosion and revenue deduction adjustments; core operating income +1% (cc, +1% USD)","length":134,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Priority brands continued their strong momentum including Kisqali (+44% cc), Kesimpta (+27% cc), Pluvicto (+70% cc), Scemblix (+87% cc) and Cosentyx (+11% cc)","length":158,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":1...